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Abstract: As a part of an abnormal healing process of dermal injuries and irritation, keloid scars
arise on the skin as benign fibroproliferative tumors. Although the etiology of keloid scarring
remains unsettled, considerable recent evidence suggested that keloidogenesis may be driven by
epigenetic changes, particularly, DNA methylation. Therefore, genome-wide scanning of methylated
cytosine-phosphoguanine (CpG) sites in extracted DNA from 12 keloid scar fibroblasts (KF) and
12 control skin fibroblasts (CF) (six normal skin fibroblasts and six normotrophic fibroblasts) was
conducted using the Illumina Human Methylation 450K BeadChip in two replicates for each sample.
Comparing KF and CF used a Linear Models for Microarray Data (Limma) model revealed 100,000
differentially methylated (DM) CpG sites, 20,695 of which were found to be hypomethylated and 79,305
were hypermethylated. The top DM CpG sites were associated with TNKS2, FAM45B, LOC723972,
GAS7, RHBDD2 and CAMKK1. Subsequently, the most functionally enriched genes with the top
100 DM CpG sites were significantly (p ≤ 0.05) associated with SH2 domain binding, regulation of
transcription, DNA-templated, nucleus, positive regulation of protein targeting to mitochondrion,
Biomedicines 2020, 8, 181; doi:10.3390/biomedicines8070181 www.mdpi.com/journal/biomedicines
Biomedicines 2020, 8, 181 2 of 16
nucleoplasm, Swr1 complex, histone exchange, and cellular response to organic substance. In addition,
NLK, CAMKK1, LPAR2, CASP1, and NHS showed to be the most common regulators in the signaling
network analysis. Taken together, these findings shed light on the methylation status of keloids that
could be implicated in the underlying mechanism of keloid scars formation and remission.
Keywords: keloid scars; DNA methylation; wound healing; epigenetics
1. Introduction
Wound healing in the human body is one of the most complex and progressive processes
that require the involvement of several different molecular and cellular events [1,2]. The normal
healing process involves multi-dynamic stages in three overlapping phases: the inflammation reaction,
cellular elements proliferation and synthesis, and remodeling [2,3]. The latter phase outcomes are
clinically predominant where collagen deposition occurs [4]. When the healing process is adequate,
inconspicuous harmless scars, the normotrophic, are formed [5].
In response to aberrant healing of skin injuries and irritation, undesirable scars are raised [6,7].
Scars can fall into both hypertrophic and keloids that are not necessarily the same, but can be difficult
to differentiate [4,8]. Keloids are often distinguished by their growing to the surrounding healthy skin
beyond the margins of the original tissue lesion [8,9]. Keloid scars are benign dermal fibrotic tumors
clinically characterized by the excessive production and deposition of the extracellular matrix (ECM)
components [4,10,11]. Although the pathogenesis of keloids is poorly elucidated, some genetic and
environmental factors, as well as epigenetic mechanisms, have been involved, resulting in dysregulation
of the tissue repair and regeneration processes [3,12,13].
Interests have recently progressed toward the field of cutaneous epigenetics as a vital mechanism
in regulating gene expression. DNA methylation is one of the most potent epigenetic changes that
is common in cytosine-phosphoguanine (CpG) dinucleotides in which cytosine residue is bind to a
methyl group (CH3) at position C5 [12,14]. Methylation of the DNA is essential during early normal
development and contributes to the natural phenotypic variation in humans [15,16]. The aberrant
addition (hypermethylation), or removal (hypomethylation) of the methyl group can either decrease
or increase the rate of gene expression [17,18]. Epigenetic modification, including DNA methylation,
has been observed in several human disease, including keloid scars [18–22]. These findings strongly
suggested that DNA methylation is crucial in maintaining genome stability and plays an important
role in disease pathogenesis. Most DNA methylation is known to occur at CpG sites [23].
These studies mainly focused on CpG islands methylation, which are regions with high cluster of
CpG sites. Therefore, this study was undertaken to investigate the methylation levels of CpG sites in all
genomic regions in keloid fibroblasts compared to the normal skin and normotrophic scar fibroblasts to
further understand the role of DNA methylation as an epigenetic modification in keloid pathogenesis.
2. Experimental Section
2.1. Subjects
Keloid tissue samples were obtained from 12 patients (8 males and 4 females with an average
age of 34 years) (Table 1) who were enrolled in a clinical trial which included excision of a keloid
scar. These subjects had received no previous treatment of the keloid scar within 6 months of surgical
excision. A full medical history was taken prior to excision and clinical examination was performed
by a surgeon to confirm the diagnosis of keloid scar. The causes of keloid scar include immunization
site, surgery, non-burn trauma, acne, and burn injury. Control samples (n = 12) were normotrophic
burn scar tissue (Vancouver Scar Scale: height sub-score = 0) and matched normal skin collected from
6 male subjects with an average age of 24.5 years who had sustained a previous unilateral burn injury
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(Table 1). The clinical criteria used to differentiate a keloid scar from a normotrophic scar include a
history of continuous growth outside the boundaries of the original wound and symptoms such as
pain and itch.
The study was performed in accordance with the relevant National Health and Medical Research
Council (NHMRC) of Australia’s ethical statements and guidelines. Ethical approval for all tissue
collection was obtained from the Human Research Ethics Committees of the University of Western
Australia (RA/4/1/5604; Date: 03/09/2012) and Royal Perth Hospital (EC2009/114 and EC 2012/067; Date:
03/09/2012). All participants provided written informed consent.
Table 1. Patient and keloid scar details.
Subject ID 1 Age Gender 2 Type of Tissue Site of Tissue Ethnicity
P 1 40 F keloid scar shoulder East Asian
P 2 38 F keloid scar neck (thyroid) Southeast European
P 3 29 M keloid scar forearm Hispanic
P 4 30 M keloid scar sternum Northwest European
P 5 53 M keloid scar sternum Northwest European
P 6 28 M keloid scar upper arm Northwest European
P 7 18 F keloid scar shoulder East Asian
P 8 42 M keloid scar ear Northwest European
P 9 30 M keloid scar sternum East Asian
P 10 21 M keloid scar sternum Northwest Europeanand East Asian
P 11 47 F keloid scar sternum Northwest European
P 12 29 M keloid scar sternum East Asian
C 1 29 M
normotrophic scar forearm
South East Asiannormal skin contralateral forearm
C 2 25 M
normotrophic scar forearm
Caucasiannormal skin contralateral forearm
C 3 19 M
normotrophic scar forearm
Caucasiannormal skin contralateral forearm
C 4 25 M
normotrophic scar forearm
Caucasiannormal skin contralateral forearm
C 5 30 M
normotrophic scar forearm
Caucasiannormal skin contralateral forearm
C 6 19 M
normotrophic scar forearm
Caucasiannormal skin contralateral forearm
1 P: Patient; C: Control. 2 M: Male; F: Female.
2.2. Isolation and Culture of Fibroblasts from Keloid Scar and Control Samples
Fibroblasts were isolated from fresh tissue by the explant method. This method was slightly
modified from previously published methods [24,25]. Cell growth was maintained until the second
passage (P2) and then cells were frozen in liquid nitrogen and stored until further experiments.
2.3. DNA Extraction and Bisulfate Conversion
DNA was extracted from the fibroblasts (P2) using a QIAamp DNA Mini kit (Cat. No. 51304,
Qiagen, Hulsterweg, The Netherlands) and Promega Wizard SV Genomic DNA system (Cat. No.
A2360, Promega, Madison, WI, USA) as per the manufacturers’ instructions. The quality and quantity
of extracted DNA were measured using a NanoDrop-2000 spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA). Bisulfite conversion of 800 ng of DNA was carried out on 24 samples using
the EZ DNA Methylation kit (Cat. No. D5001, Zymo Research, Irvine, CA, USA) according to the
manufacturer’s instructions.
2.4. DNA Methylation Assay
A minimum of 500 ng genomic DNA was amplified, fragmented, and hybridized onto the
Illumina Human Methylation 450K BeadChip (Cat. No. WG-314-1003, Illumina, San Diego, CA,
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USA) according to the manufacturer’s protocol (Illumina 2013). This BeadChip processes 12 samples
per array. Two replicates of the methylation assay were performed per sample. The first BeadChip
included bisulfite-converted DNA from 6 normal skin fibroblasts and 6 normotrophic fibroblasts. The
second BeadChip included bisulfite-converted DNA from 12 keloid scar fibroblasts.
2.5. Data Processing for the 450k Methylation Array
A computational R package (RnBeads) was adapted to process and analyze the raw intensity data
from methylation chip (IDAT files) [26]. The dataset was subjected to filtering procedures, background
subtraction, and normalization. The filtering stages included the removal of sites overlapped with SNPs,
greedycut algorithm, the removal of probes with specific contexts and missing values, and the removal
of probes with beta values exhibiting standard deviation lower than 0.005. The methylumi package
(method “noob”) was used for background subtraction and the Beta-Mixture Quantile Normalization
(BMIQ) method was used to normalize the methylation beta values. As keloid fibroblasts and control
fibroblasts were run on separate BeadChips, a batch effect may occur. RnBeads uses the Surrogate
Variable Analysis (SVA) package to visualize and adjust for batch effects during differential methylation
analysis. As a final outcome, a summary of the changes at CpG sites was generated.
2.6. Differential Methylation Statistical Analysis
Differential methylation (DM) analysis comparing keloid fibroblast (KF) DNA with control
fibroblasts (CF) DNA was carried out at the CpG site. The comparison was computed using a Linear
Models for Microarray Data (Limma) method [27], which has been adapted by the RnBeads package
for use in methylation arrays. The linear models were employed and fitted using an empirical Bayes
approach on derived M-values. The Benjamini and Hochberg (B-H) 5% false discovery rate (FDR)
was used to correct for multiple testing. The DM for each CpG sites was computed based on three
measures: the beta difference in methylation means between KF and CF, the log2 of the quotient in
methylation, and the differential methylation p-value using Limma. Using these three measures, each
CpG site was given a rank. The combined rank was computed as the maximum (=worst) rank among
the three ranks. A smaller combined rank indicates that the CpG sites exhibit more DM [26]. The
top-ranking 100,000 sites with the smallest combined rank score were selected for further analysis.
2.7. Enrichment and Pathway Analysis
The Database for Annotation, Visualization, and Integrated Discovery (DAVID) v.6.8 [28,29], was
utilized to conduct GO term enrichment analysis of the genes corresponding to the top 100 CpG sites.
The GO terms included three criteria: biological process (BP), cellular component (CC), and molecular
function (MF). A p-value ≤ 0.05 was used as a cut-off threshold.
2.8. Interaction Network Analysis
The interaction network analysis of genes associated with the top 100 DM CpG sites was explored
using the Signaling Network Open Resource 2.0 (SIGNOR) [30]. The type of relation was selected to
include only “all” interactions with a relaxed layout and score of “0.0”.
3. Results
3.1. Samples Clustering
The samples sharing similar methylation patterns showed an expected hierarchal clustering based
on all the methylation values of the top 1000 most variable loci (Figure 1). In a study conducted by our
research group, we have found no statistical significance in methylation level between normotrophic
burn scar fibroblasts and matched normal skin fibroblasts (data not published). Hence, fibroblasts
from both tissue types (normotrophic burn scar and normal skin) were used in this study as CF to
increase statistical power. Figure 1 shows one hierarchal clustering of CF isolated from normotrophic
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burn scar and normal skin explaining the similarity in methylation patterns and another clustering of
KF isolated from keloid scar. The dataset was inspected for a strong signal in the methylation values
using a dimension reduction test by implementing multidimensional scaling (MDS) method (Figure 2).
MDS confirmed that the difference in methylation level between KF and CF dominates the analysis.
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3.2. Differential Methylation of CpG Sites
The top 100,000 sites ranked according to the combined rank score were selected to identify DM
CpG sites in KF. Of the 100,000 CpG sites, 20,695 CpG sites were found to be hypomethylated (beta
difference range = −0.030 to −0.67) and 79,305 CpG sites were hypermethylated (beta difference range
= 0.030 to 0.79) in KF compared to CF with an adjusted p-value (FDR) ≤0.11 (Figure 3). The log2 of the
quotient in methylation between KF and CF had a minimum value of −3.34 and a maximum value of
4.42. The top 100 DM CpG sites with the lowest combined rank score are shown in Table S1. The beta
difference of the list of 100 DM sites ranged from −0.22 to −0.42 for hypomethylated genes and ranged
from 0.23 to 0.60 for hypermethylated genes with an adjusted p-value (FDR) ≤1.72 × 10−6.
3.3. Functional Enrichment Analysis
The genes associated with the top 100 DM CpG sites were subject to functional enrichment
analyses using the DAVID webtool. The most significant gene ontology (GO) terms (p-value ≤ 0.05)
are shown in Table 2. On the MF level, the associated genes were mainly enriched for “SH2 domain
binding”, on the CC level, genes were enriched for “nucleus”, “nucleoplasm”, and “Swr1 complex”. On
the BP level, the associated genes were enriched for four terms including “regulation of transcription,
DNA-templated”, “positive regulation of protein targeting to mitochondrion”, “histone exchange”,
and “cellular response to organic substance”.
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Table 2. Gene ontology enrichment analyses of the genes associated with the top 100 CpG sites.
Category 1 Term p-Value 2 Genes
MF GO:0042169~SH2 domain binding 0.002 SYP, NLK, DAG1
BP GO:0006355~regulation oftranscription, DNA-templated 0.005
ASXL2, PKNOX2, ZNF718, BPTF,
TFEC, NLK, SCML1, GAS7,
BRD8, KLF3
CC GO:0005634~nucleus 0.011




TAF15, BPTF, C19ORF66, USP36,
FANCC, BRD8, MYH10, KLF3
BP
GO:1903955~positive regulation
of protein targeting to
mitochondrion
0.016 HSPA1L, NBPF3, USP36
CC GO:0005654~nucleoplasm 0.020
ASXL2, NLK, FA K1, DAG1,
TKT, HSPA1L, PSMA1, SENP1,
BPTF, TAF15, TFEC, BRD8,
FANCC
CC GO:0000812~Swr1 complex 0.021 ANP32E, BRD8
BP GO:0043486~histone exchange 0.025 ANP32C, ANP32E
BP GO:0071310~cellular response toorganic substance 0.038 SY , CASP1
1 BP: biological process; CC: cellular component; MF: molecular function; 2 Terms with a p-value ≤ 0.05 are shown.
3.4. Interaction Network
Analysis of the interaction between the genes associated with the top 100 DM CpG sites showed
that five genes were found to be common regulators with a minimum of 7 connectivities each. These
genes are the NLK, CAMKK1, LPAR2, CASP1 and NHS genes (Figure 4).
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4. Discussion
Keloid scar ing is an aggressive skin dise s it l t i . It is characterized by
exces ive fibroblast proliferatio a c ll i i t e that does not regre s over
time [31]. Keloid scars are a o i it o single effective treatment regimen.
Nevertheles , clin cians use veral modalities for sca prevention and manage e t, including massa e
therapy, pressure garments, adhesive tape suppor /silicone gel sheeti g, intralesio al cortico teroid
injections, laser a d light-based therapy, cryotherapy, radiotherapy, 5-fluorouracil, interferon injections,
bleomycin i j ti and surgery [32]. Amo g thes wide treatmen strategies, intral sional steroid
injections remain the first-l ne treatment for many clinicians alone or i combination with other
treatment modalities [33]. A wid ly use intralesional corticosteroi is tri mcinolone acetonide [33].
Treatment with triamcinolone alone proved to be more effective than verapamil for the prevention
of keloid scar recurrence after surgical excision [34]. Compared to 5-fluorouracil and bleomycin,
triamcinolone is more effective in preventing recurrence and reducing scar size and symptoms [33].
However, a combined treatment of triamcinolone with other treatment modalities such as verapamil,
5-fluorouracil, and laser therapy showed better outcomes and patient satisfaction [33]. Depending on
the size and location of scars, the recommended concentration of triamcinolone ranges from 10 to 40
mg/mL [35].
Unlike genetic alterations, epigenetic changes are potentially reversable [36]. Therefore, the
identification of epigenetic targets could lead to therapeutic interventions. DNA methylation is an
epigenetic gene regulatory mechanism that has been found to play a fundamental role in cancer [37],
fibrotic disorders [15,38,39], cutaneous diseases [18,22,40–42], and wound healing [20,43]. DNA
methylation is known to occur commonly at CpG islands and was traditionally linked to transcriptional
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silencing. These CpG islands are found in high densities in the promoter regions of genes, where
transcription of DNA begins, and thus regulate gene transcription [44,45]. This study has explored
whether altered collagen deposition by keloid fibroblasts could at least in part be explained by
epigenetic changes sustainably and heritably altering the gene expression profile in these cells. Our
findings showed significant DNA methylation changes at the CpG sites across multiple genes in KF
DNA compared to CF DNA.
The overgrowth and hyperproliferative nature of keloids are common features with tumorigenesis,
in addition to epigenetic and genetic aberration. Of the differentially methylated 100,000 CpG sites in
our analysis, more than two-thirds were hypermethylated. Consistent with several cancers-linked
DNA hypermethylation, such as in prostate cancer (PCa) [46], and breast cancer [47]. In contrast, more
hypomethylation profiles found in keloids genome, frequently in the non-promoter regions [17].
Among the 100 top-ranking DM CpG sites in KF compared to CF, the top seven genes were
tankyrase 2 (TNKS2), hepatopoietin PCn127 (LOC723972), family with sequence similarity 45 member
B (FAM45B), growth arrest specific 7 (GAS7), neuroblastoma breakpoint member 3 (NBPF3), rhomboid
domain containing 2 (RHBDD2), and family with sequence similarity 64 member A (FAM64A).
TNKS2 (cg11963436) and LOC723972 (cg21581312) were reported to be among the 50 DM CpG sites
associated with lung function in cystic fibrosis patients [48]. From a methylation-based Epigenome-Wide
Association Study (EWAS) in Parkinson’s disease (PD) identifying 9983 DM genes, FAM45B, LOC723972,
and TNKS2 were among 20 unique DM genes in the patients. In further evaluation, TNKS2 (cg11963436)
was one of two significantly confirmed DM genes that hypermethylated in PD patients [49]. Using the
Illumina Human Methylation 450K BeadChip, LOC723972 (cg21581312) CpG site was hypomethylated
in cervical squamous cell carcinoma (SCC) as well as in cervical intraepithelial neoplasia grade 3
(CIN3) compared with the normal tissues [50]. Methylation profiles in colorectal cancer (CRC) showed
50 significantly hypermethylated CpG sites located within six genes in African American patients,
including GAS7 gene [51]. Moreover, among 355 methylated CpG sites in CRC, GAS7 was one of 59
significantly methylated sites in CRC tissues compared to normal tissues [52]. Furthermore, several
epigenomic analyses revealed the hypermethylation pattern of GAS7 in lung cancer [53,54], prostate
cancer [55], CRC [56], and pancreatic endocrine tumors (PETs) [57]. In order to investigate the strong
association of the obesity-associated (FTO) gene variants and obesity with epigenetic changes, a
genome-wide methylation scan in obese and normal weight females identified 20 DM sites in obese
females, of which one was hypomethylated site in NBPF3 gene [58]. There are little or no reports on the
methylation status of RHBDD2, but it was found to be overexpressed in CRC [59], breast cancer [60,61],
and as a pathogenic gene in familial non-medullary thyroid cancer (FNMTC) [62]. The FAM64A gene
correlated in differentially methylated regions (DMRs) containing multiple CpG sites associated with
nevus count (n-DMRs), which is a strong risk factor, contributed to melanoma pathogenesis [63].
An interaction network analysis of the top 100 DM CpG sites showed five common regulator genes:
nemo-like kinase (NLK), calcium/calmodulin-dependent protein kinase 1 (CAMKK1), lysophosphatidic
acid receptor 2 (LPAR2), caspase 1 (CASP1), and Nance-Horan syndrome (NHS). The mitogen-activated
protein kinase (MAPK) member, NLK is involved in a variety of signaling pathways as well as in
several types of cancer. NLK was found to positively regulate the activation of CCAAT/enhancer
binding proteins (C/EBPs) signaling cascade triggered by the proinflammatory cytokine, interleukin-1
(IL-1) [64]. In contrast, it was found to negatively regulate the ternary transcriptional complex in the
Notch signaling pathway that is crucial in cell fates of metazoan tissues [65]. Aberrant expression
of NLK has been associated with the initiation or progression of oral squamous cell carcinoma [66],
laryngeal cancer [67], non-small-cell lung cancer (NSCLC) [68,69], and CRC [70]. The CAMKK1 gene
mediated the upstream activation of AMP-activated protein kinase (AMPK) by phosphorylation of
the α-subunit threonine 172 (Thr172) residue. AMPK is a key regulator in various cellular events and
targets, such as in the treatment of type 2 diabetes (T2D) and maintaining homeostasis of the cellular
energy [71,72]. The expression levels of LPAR2 have a critical role in carcinogenesis and during tumor
progression [73–77]. In a mouse model, overexpression of LPAR2 induces intestinal dysplasia, which
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therefore alters the proliferation and differentiation of the intestinal epithelial cells (IEC) [78]. The
pivotal inflammasome component, Caspase-1, is an emerging player in various diseases progressions,
as well as a biomarker for early diagnosis and a therapeutic target [79–82]. The encoded protein of
the NHS gene regulates the development of brain, craniofacial, eye, and tooth, in addition to actin
remodeling and thus maintaining cell morphology. Mutations in the NHS gene were found to cause
Nance–Horan syndrome (NHS), an X-linked disorder [83–88].
Ontology enrichment analysis of the genes provides insight into the role of the significantly
methylated genes, showed that hypo- and hypermethylated CpG sites have occurred at various
categories of biological processes, cellular components, and molecular functions. The most relevant
genes class was associated with the Src-homology 2 (SH2) domain binding (GO:0042169). Interestingly,
the genes in SH2 domain binding were hypermethylated (Table S1). Among them is the synaptophysin
(SYP) gene, where SH2 domains bind to its multiple carboxyterminal tyrosine-phosphorylated
residues [89]. SH2 domains are involved in various signaling transduction and found to regulate
cellular behavior and functions upon interactions with other domains and cellular components [90].
However, the SYP gene is a pivotal regulator in the release of neurotransmitters and synaptic plasticity.
It was found to be associated with some psychiatric disorders such as attention-deficit/hyperactivity
disorder (ADHD) [91], schizophrenia [92], and depression [93]. Other prevailing ontological terms are
the regulation of transcription, DNA-templated (GO:0006355) and histone exchange (GO:0043486).
The latter of which process genes, acidic nuclear phosphoprotein 32 family member C and member E
(ANP32C and ANP32E, respectively) and were also hypermethylated (Table S1). They were frequently
found to regulate gene expression by acting on the substitution of histones or histone subunits within the
chromatin, especially the ANP32E gene [94–96]. The ANP32E gene was enriched in two other cellular
component terms, nucleus (GO:0005634) and Swr1 complex (GO:0000812). Although some ANP 32
family members function as tumor suppresser, ANP32C is an oncogene that has been overexpressed
in prostate and breast cancer [97,98]. In a similar context, ANP32E is found to induce oncogenesis of
triple-negative breast cancer (TNBC) by upregulation of the transcription factor, E2F1 [99]. Furthermore,
those genes belong to the regulation of transcription, DNA-templated ontology, were represented by
hypo- and hypermethylation patterns (Table S1). Among them is the ASXL transcriptional regulator 2
(ASXL2) gene, in which de novo germline truncation in ASXL2 variants have been associated with
various clinical features of intellectual disabilities, macrocephaly, and dysmorphism [100]. Similarly,
ASXL2 deficiency in mice model (ASXL2−/−) was directed towards insulin resistance, osteopetrosis,
and lipodystrophy [101]. Moreover, it promotes breast carcinogenesis through epigenetic regulation of
the estrogen receptor alpha (ERα) [102].
5. Conclusions
In addition to the preliminary known genetic predisposition of keloids, methylation sequencing of
CpG sites in keloids revealed significant hyper- and hypomethylated genes in fibroblasts from keloid
scars compared to control fibroblasts demonstrated the vital role of DNA methylation as an epigenetic
regulation mechanism in keloids formation and progression, as well as a putative therapeutic target,
by reversing the methylation status to halt the overgrowth in scars. The DM genes and their products
are known to elaborate several biological pathways, signaling, and functions that could be implicated
further to understand keloid etiology and targeted treatment development in future exploration.
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